Alcon to Acquire LumiThera

LumiThera Acquires MacuLogix Assets (AdaptDx Pro)

July 26, 2022

Medical Devices

LumiThera, through a wholly owned subsidiary, purchased the assets of MacuLogix, including the AdaptDx Pro dark adaptometer used for early diagnosis of dry age-related macular degeneration (AMD). The acquisition expands LumiThera's diagnostic and monitoring capabilities and complements its Valeda photobiomodulation treatment platform for dry AMD patients.

LumiThera Acquires Diopsys

November 11, 2021

Medical Devices

LumiThera, a commercial-stage ophthalmic medical device company, entered a definitive merger agreement to acquire Diopsys in a stock-for-stock transaction under which Diopsys will become a wholly owned subsidiary of LumiThera. The deal combines Diopsys' visual electrophysiology diagnostic systems with LumiThera's photobiomodulation treatment platform to create a coordinated light-based theranostic approach for diagnosing, treating and monitoring ocular disease.

Luminii Acquires Alva Lighting

March 11, 2026

Manufacturing

Luminii, backed by private equity firm The Cambria Group, quietly acquired Alva Lighting, a California maker of indoor and outdoor wall sconces. The transaction appears to be another buy-and-build add-on to Luminii’s growing portfolio of architectural lighting brands.

Alcon Agrees to Acquire LENSAR, Inc.

March 24, 2025

Medical Devices

Alcon and LENSAR entered into a definitive merger agreement under which Alcon intends to acquire LENSAR for $14.00 per share in cash, plus a contingent value right that could add up to $2.75 per share. The total potential consideration is approximately $430 million, and the deal is expected to close in mid-to-late 2025 subject to customary approvals and LENSAR stockholder approval.

Alcon Acquires Majority Interest in Aurion Biotech, Inc.

March 26, 2025

Biotechnology

Alcon has acquired a majority interest in clinical-stage Aurion Biotech to accelerate development and commercialization of Aurion's allogeneic corneal cell therapy AURN001. Aurion will remain a separate company while leveraging Alcon's global R&D, regulatory and commercial capabilities to advance AURN001 into U.S. Phase 3 development in the second half of 2025.

Alcon Acquires Aerie Pharmaceuticals, Inc.

August 22, 2022

Healthcare Services

Alcon entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, adding Rocklatan and Rhopressa commercial products along with AR-15512 and other ophthalmic pharmaceutical pipeline assets. The deal was funded with debt and was expected to close in Q4 2022, subject to customary approvals and conditions.